Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3454 in Advanced Solid Tumors
NCT07738679Phase 2Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3454 in solid tumor, glioma, biliary tract cancer (BTC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
TQB3454
03
Conditions
solid tumorgliomabiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07738679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738679.